[Chemotherapy induced ovarian failure in breast cancer: Retrospective study of 100 cases].

L’insuffisance ovarienne chimio-induite dans le cancer du sein : étude rétrospective de 100 cas.
Aménorrhée chimio-induite Breast cancer Cancer du sein Chemotherapy induced amenorrhea Fertility Fertilité Patientes préménopausées Premenopausal women

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 08 06 2019
revised: 17 05 2020
accepted: 27 05 2020
pubmed: 9 8 2020
medline: 2 10 2020
entrez: 9 8 2020
Statut: ppublish

Résumé

Breast cancers affect about a quarter of women of reproductive age worldwide. Chemotherapy is frequently indicated due to the aggressive biomolecular cancer subtypes usually observed in the localized forms, which may compromise the fertility of these young patients. The aim of our study is to report the incidence of chemotherapy induced ovarian failure in premenopausal breast cancer patients after chemotherapy, and to identify related risk factors. It is a retrospective cross-sectional cohort study which included all premenopausal patients with early breast cancer treated at the department of medical oncology, Hassan II University Hospital of Fez, during a period of one year. Chemotherapy induced amenorrhea (CIA) and associated risk factors were studied. The study included 100 patients. The mean age of the subjects was 36 years. The incidence of CIA was 82 %, 66.7 % regained menstruations. Risk factors associated with CIA were analyzed, only the patient age at diagnosis was found to be statistically significantly associated with CIA. Our study found a high incidence of CIOF (Chemotherapy-induced ovarian failure) with a relatively low incidence of reversible amenorrhea. Only the patient age has been shown to be an independent factor, statistically significantly associated with ovarian failure after chemotherapy. Methods of fertility preservation should be considered in those patients to reduce the impact of chemotherapy on ovarian reserves.

Identifiants

pubmed: 32762944
pii: S0007-4551(20)30296-4
doi: 10.1016/j.bulcan.2020.05.011
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

854-860

Informations de copyright

Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Lamiae Amaadour (L)

CHU Hassan II de Fès, service d'oncologie médicale, Maroc. Electronic address: lamiae.amaadour@gmail.com.

Fatima Zahra El Mrabet (FZ)

CHU Hassan II de Fès, service d'oncologie médicale, Maroc.

Loubna Atreche (L)

CHU Hassan II de Fès, service d'oncologie médicale, Maroc.

Karima El Rhazi (K)

CHU Hassan II de Fès, service d'oncologie médicale, Maroc.

Karima Oualla (K)

CHU Hassan II de Fès, service d'oncologie médicale, Maroc.

Zineb Benbrahim (Z)

CHU Hassan II de Fès, service d'oncologie médicale, Maroc.

Samia Arifi (S)

CHU Hassan II de Fès, service d'oncologie médicale, Maroc.

Nawfel Mellas (N)

CHU Hassan II de Fès, service d'oncologie médicale, Maroc.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH